Spironolactone in Covid-19 Induced ARDS

Istanbul University - Cerrahpasa (IUC)

Status and phase: Completed; Phase 4

Conditions: Respiratory Distress Syndrome, Adult

Treatments: Drug: Spironolactone 100mg; Drug: Placebo oral tablet

Study type: Observational

Funder types: Other

Identifiers

NCT04345887

10042020

Details and patient eligibility

About

This study intended to evaluate the effects of commonly used diuretic, spironolactone, on oxygenation in covid-19 ARDS patients.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hemodynamically stable
• Hypoxemia, i.e. p/f <150
• Admitted to ICU within 48 hours
• Not moribund has a life expectancy greater than 24 hours

Exclusion criteria

• Age criteria
• Pregnancy
• Unwillingness to participate

Trial design

60 participants in 2 patient groups

Spironolactone

Description:

2 x 100 mg spironolactone

Treatment:

Drug: Spironolactone 100mg

Placebo

Description:

2 x 1 placebo

Treatment:

Drug: Placebo oral tablet